中药联合利拉鲁肽治疗2型糖尿病合并肥胖的Meta分析

A Meta-analysis of Traditional Chinese Medicine Combined with Liraglutide in the Treatment of Type 2 Diabetes Mellitus Complicated with Obesity

目的系统性评价中药联合利拉鲁肽治疗2型糖尿病合并肥胖的临床疗效。方法计算机检索中国知网、万方、维普、PubMed等数据库,选出中药联合利拉鲁肽治疗2型糖尿病合并肥胖的随机对照试验相关文献,检索年限为各数据库建库-2023年1月。通过Revman5.4软件分析数据。结果共纳入9项随机对照试验(n=699)。Meta分析显示,与使用利拉鲁肽的对照组相比较,经中药联合利拉鲁肽治疗的试验组在降低空腹血糖[MD=-1.11,95%CI(-1.25,-0.97),P<0.00001]、餐后2h血糖[MD=-1.23,95%CI(-1.41,-1.05),P<0.00001]、糖化血红蛋白[MD=-0.92,95%CI(-1.42,-0.42),P=0.0003]、体质量指数[MD=-1.29,95%CI(-1.76,-0.82),P<0.00001]、胰岛素抵抗指数[SMD=-2.44,95%CI(-4.09,-0.79),P=0.004]方面效果更显著,在提高临床有效率(OR=4.21,95%CI[2.14,8.29],P<0.0001)方面效果更显著。结论中药联合利拉鲁肽在降低2型糖尿病合并肥胖患者血糖水平、体质量指数,以及提高临床有效率方面明显优于单用利拉鲁肽。

Objective:To systematically evaluate the clinical effect of traditional Chinese medicine combined with Liraglutide in the treatment of type 2 diabetes mellitus complicated with obesity.Methods:The literature related to randomized controlled trials of traditional Chinese medicine combined with liraglutide in the treatment of type 2 diabetes mellitus with obesity were selected from CNKI,Wanfang,VIP,PubMed and other databases.The retrieval period was January 2023 and the data were analyzed by Revman5.4 software.Results:A total of 9 randomized controlled trials were included(n=699).Meta-analysis showed that when compared with the control group treated with liraglutide,the experimental group treated with traditional Chinese medicine combined with liraglutide had significantly lower fasting blood glucose[MD=-1.11,95%CI(-1.25,-0.97),P<0.00001]and 2h postprandial blood glucose[MD=-1.23,95%CI(-1.41,).-1.05),P<0.00001],HBA1c[MD=-0.92,95%CI(-1.42,-0.42),P=0.0003],body mass index[MD=-1.29,95%CI(-1.76,-0.82),P<0.00001],insulin resistance index[SMD=-2.44,95%CI(-4.09,-0.79),P=0.004],and clinical response rate[OR=4.21,95%CI(2.14,8.29),P<0.0001]were more significant.Conclusion:Traditional Chinese medicine combined with Liraglutide is superior to liraglutide alone in reducing blood glucose level,body mass index and improving clinical effective rate in type 2 diabetes mellitus patients with obesity.